Xbrane Biopharma AB Tangible Net Worth Ratio
Xbrane Biopharma AB tangible net worth ratio. Xbrane Biopharma AB (XBRANE) has a Tangible Net Worth Ratio of 41.6% as of June 2026. This metric is calculated by deducting intangible assets (Skr314.82 Million) from net assets (Skr538.85 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check XBRANE capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Xbrane Biopharma AB (2012–2025)
Tangible net worth ratio of Xbrane Biopharma AB from 2012 to 2025. This chart shows how Xbrane Biopharma AB's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 41.6%, reflecting net assets of Skr538.85 Million with intangible assets of Skr314.82 Million SEK. See XBRANE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Xbrane Biopharma AB Tangible Net Worth Ratio by Year (2012–2025)
Xbrane Biopharma AB tangible net worth ratio by year from 2012 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market value of Xbrane Biopharma AB.
| Year | Tangible NW Ratio | Net Assets (SEK) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 47.1% | Skr560.65 Million | Skr296.46 Million | Skr671.62 Million | ▲ +27.5 pp |
| 2024 | 19.6% | Skr208.54 Million | Skr167.69 Million | Skr842.43 Million | ▼ -22.2 pp |
| 2023 | 41.8% | Skr171.34 Million | Skr99.67 Million | Skr653.51 Million | ▼ -34.2 pp |
| 2022 | 76.0% | Skr424.89 Million | Skr102.00 Million | Skr690.51 Million | ▼ -12.5 pp |
| 2021 | 88.5% | Skr431.74 Million | Skr49.67 Million | Skr688.43 Million | ▼ -9.9 pp |
| 2020 | 98.4% | Skr257.71 Million | Skr4.08 Million | Skr463.76 Million | ▲ +1.2 pp |
| 2019 | 97.3% | Skr184.32 Million | Skr5.05 Million | Skr338.94 Million | ▲ +4.2 pp |
| 2018 | 93.1% | Skr83.07 Million | Skr5.77 Million | Skr252.88 Million | ▲ +0.2 pp |
| 2017 | 92.9% | Skr88.41 Million | Skr6.30 Million | Skr110.96 Million | ▲ +0.8 pp |
| 2016 | 92.1% | Skr107.30 Million | Skr8.46 Million | Skr118.11 Million | ▲ +4.8 pp |
| 2015 | 87.3% | Skr47.51 Million | Skr6.03 Million | Skr75.33 Million | ▼ -12.7 pp |
| 2014 | 100.0% | Skr6.30 Million | Skr0.00 | Skr6.69 Million | ▲ +0.0 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr0.00 | Skr9.20 Million | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr0.00 | Skr657.01K | — |